What Are the Biggest Challenges & Opportunities of JCA, Dr. Nick Leach?
In this brand new episode of MAP, the Market Access Podcast, our host Dr. Stefan Walzer is joined by Dr. Nick Leach, Market Access expert and managing director at Red Thread, to break down the Joint Clinical Assessment (JCA) process, its impact on pharma, biotech, and medical device companies, and how early advice can shape market access and reimbursement strategies in Europe.Tune in to learn about JCA’s mandatory requirements, challenges, opportunities, and future developments as companies prepare for the evolving EU market access framework. JCA is changing the market access landscape in Europe - don’t miss out on this insightful discussion!Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/#MarketAccess #JCA #Pharma #HealthEconomics #HTA #Reimbursement #Biotech #marketaccess #marketaccesspodcast
--------
35:42
Are We Overlooking the Real Benefits of Medical Innovation, Dr. Ahmed Seddik?
Join the latest episode of the Market Access Podcast, where our host Dr. Stefan Walzer and expert Dr. Ahmed Seddik dissect the complexities of the societal impact of medical innovation. Dr. Ahmed Seddik shares important insights from his journey starting as a dentist in Egypt to his PhD research in health economics and social impact, focusing on how the access to innovation transforms communities and economies.Explore how medical innovation shapes healthcare systems and economies, and take part in the discussion of how health economics, cost-effectiveness, and societal impact influence reimbursement decisions. Listen now to learn more about how different countries integrate social value into healthcare policies and what the future holds for market access and innovation adoption.Curious to explore this topic further? You can find Ahmed Seddik’s thesis here: The social impact of medical innovationsStay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/#MarketAccess #HealthEconomics #MedicalInnovation #SocialImpact #HealthcarePolicy #marketaccess #marketaccesspodcast
--------
33:42
What Are the Biggest Challenges in Implementing AI in Pharma, Jan Kroschinski?
How can AI revolutionize Market Access, and what does it take to drive successful change in pharma? Tune into the latest episode of MAP, the Market Access Podcast, where our host Dr. Stefan Walzer and Jan Kroschinski, an expert in digital transformation, will delve into change management and AI adoption in pharma.Follow along as they explore how AI can streamline processes like dossier writing and HTA submissions, while tackling resistance to change. Discover strategies for effective AI adoption, leadership engagement, and risk vs. opportunity - how to shift from fear-based thinking to opportunity-driven AI adoption. Get ahead of the AI curve with this insightful discussion!Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/#MarketAccess #AI #DigitalTransformation #ChangeManagement #Pharma #HealthTech #marketaccess #marketaccesspodcast
--------
43:38
How Can Startups Leverage Market Access to Attract Investors, Johan Olsson?
In the latest episode of MAP, the Market Access Podcast, our host Dr. Stefan Walzer sits down with Johan Olsson, a seasoned life sciences investor, to uncover the critical role of market access and reimbursement in early-stage healthcare investments.They explore how early market access planning impacts healthcare startups, investment decisions, and commercialization success. Discover why pricing, reimbursement, and payer strategies are key to securing funding, mitigating risk, and maximizing valuation. An understanding of the market access landscape can make or break a healthcare startup’s valuation, funding potential, and commercial viability. Tune in now to learn how to navigate market access for healthcare investments!Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/#MarketAccess #HealthcareInvestments #BiotechStartups #ReimbursementStrategies #Commercialization #AIHealthcare #marketaccess #marketaccesspodcast
--------
33:03
How Are Data Privacy Laws Delaying Patient Access to New Treatments, Douglas Drake and Adam Skali?
In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data privacy challenges, delays in commercialization, and the future of healthcare data regulation. Learn more about how data privacy laws create barriers for cross-border studies, delaying access to life-saving treatments, and how companies can navigate these hurdles and optimize market entry strategies. Can Europe find a balance between data privacy and innovation? Tune in to explore the challenges, solutions, and what’s next for healthcare in the EU.Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/#GDPR, #MarketAccess, #Real-WorldEvidence, #HealthcareData, #Pharma, #MedTech, #Cross-BorderStudies #marketaccess #marketaccesspodcast
Market Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world.
MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market access , reimbursement and pricing issues in the D-A-CH countries and around the world. With MAP you will get a summary of core market access systems and processes as well as latest changes in regulations including statements and opinions of core decision makers and stakeholders from various countries.
The CEO and founder of MArS is also the driver behind MAP: Dr. Stefan Walzer works in the field of payer strategy, pricing, health economics and reimbursement since 2004 and is the founder and CEO of MArS Market Access & Pricing Strategy GmbH based in Germany. MArS makes it as easy as possible for you to get your Pharmaceutical, MedTech or digital health product to the market and of course get the price it deserves.
Stefan previously worked as a payer consultant for various global pharmaceutical and medical device / diagnostic companies, successfully launching their products across the world. He was the Global Payer Strategy Leader for various products and compounds at F. Hoffmann – La Roche AG, where he successfully developed early payer strategies as well as launching and maintaining the reimbursement process for top brands and early compounds. Stefan is capable in translating the clinical and economic evidence into successful reimbursement submissions and pricing negotiations especially in Austria, Germany and Switzerland. Additionally he teaches market access, pricing and negotiations at the State University of Baden-Wuerttemberg and the University of Applied Sciences Weingarten-Ravensburg (both Germany).
Besides other roles and responsibilities. Stefan was the head of the committee “Inpatient care” of the German Health Economic Association (DGGÖ). Furthermore he is also a member of the Austrian Health Economic Association (ATHEA) and the Swiss Health Economic Association (SGGÖ). Additionally, he is a member of the Access Advisory Committee of the Global Pneumonia Prevention Coalition.
Stefan received a Master of Science in Economics from the University of Tuebingen (Germany), a PhD in Health Economics from the University of Zurich (Switzerland) and a post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine (UK). He is co-author of more than 40 peer-reviewed scientific articles and more than 300 scientific abstracts.
Canada - english